After mega-round investment, ADC Therapeutics cans PhI trial in HER2
After raising a $200 million mega-round just months ago, Swiss drugmaker ADC Therapeutics is axing one of its programs due to toxicity issues.
The cut …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.